Hillsdale Investment Management Inc. Neurocrine Biosciences Inc Transaction History

Hillsdale Investment Management Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$130.4 - $143.74 $6,520 - $7,187	-50 Reduced 1.04%	4,760 $656,000
Q4 2023 Feb 09, 2024	BUY	$106.07 - $132.76 $510,196 - $638,575	4,810 New	4,810 $633,000
Q1 2023 May 10, 2023	BUY	$94.11 - $123.02 $37,644 - $49,208	400 Added 10.15%	4,340 $439,000
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $405,536 - $482,828	3,800 Added 2714.29%	3,940 $470,000
Q2 2022 Aug 12, 2022	BUY	$75.79 - $100.07 $10,610 - $14,009	140 New	140 $14,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.